The USC Norris Comprehensive Cancer Center (NCCC) is requesting $450,000 per year in Developmental Funds to be used for new investigator support to recruit faculty level scientists in areas of strategic need and to fund innovative pilot projects. These funds will be crucial to our success as we continue to expand the number of investigators supported by the NCCC to fill the newly constructed research space in the Harlyne Norris Research Tower (HNRT). The HNRT is approximately 70% occupied and still has space for an additional 15 investigators. All recruitments are strategic to the NCCC's goals and have been discussed at our leadership retreats, approved by our Cancer Center Leadership Council and Cancer Center Executive Committee and evaluated by our External Advisory Committee. We will allocate our new investigator support annually at the recommendation of the Cancer Center Director and with the advice of our External Advisory Committee and the approval of the Executive Committee. Pilot project funds will be allocated after the review and recommendation for funding by the Leadership Council through the Whittier Initiative. Developmental Funds awarded during the past five years were allocated primarily to the recruitment of new investigators. The remaining portion was used to fund innovative pilot projects and to establish new shared resources.
Developmental Funds allow the NCCC to fund innovative pilot projects and hire additional investigators to perform translational research for the development of more effective prevention, diagnosis, treatment of cancer.
|Thomas, Duncan C (2017) Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer. Epidemiology 28:470-478|
|Thomas, Duncan C (2017) What Does ""Precision Medicine"" Have to Say About Prevention? Epidemiology 28:479-483|
|Bensman, Timothy J; Jayne, Jordanna G; Sun, Meiling et al. (2017) Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother 61:|
|Liang, Gangning; Weisenberger, Daniel J (2017) DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics 12:416-432|
|Schwitzer, Emily; Orlow, Irene; Zabor, Emily C et al. (2017) No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. Pigment Cell Melanoma Res 30:424-427|
|Okazaki, Satoshi; Stintzing, Sebastian; Sunakawa, Yu et al. (2017) Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer 141:1222-1230|
|Poulard, Coralie; Bittencourt, Danielle; Wu, Dai-Ying et al. (2017) A post-translational modification switch controls coactivator function of histone methyltransferases G9a and GLP. EMBO Rep 18:1442-1459|
|Kim, Yong-Mi; Gang, Eun-Ji; Kahn, Michael (2017) CBP/Catenin antagonists: Targeting LSCs' Achilles heel. Exp Hematol 52:1-11|
|Reid, Brett M; Permuth, Jennifer B; Chen, Y Ann et al. (2017) Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 26:116-125|
|Stueve, Theresa Ryan; Li, Wen-Qing; Shi, Jianxin et al. (2017) Epigenome-wide analysis of DNA methylation in lung tissue shows concordance with blood studies and identifies tobacco smoke-inducible enhancers. Hum Mol Genet 26:3014-3027|
Showing the most recent 10 out of 739 publications